Hurler Syndrome

14 registered clinical trials studyying Hurler Syndrome.

Status	Trial	Sponsor	Phase
Suspended	RGX-111 Gene Therapy in Patients With MPS I NCT03580083	REGENXBIO Inc.	Phase 1 / Phase 2
Completed	Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation NCT03513328	University of Florida	Phase 1 / Phase 2
Active Not Recruiting	MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis NCT02171104	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	Bone Marrow Transplant With Abatacept for Non-Malignant Diseases NCT01917708	Emory University	Phase 1
Completed	Administration of IV Laronidase Post Bone Marrow Transplant in Hurler NCT01173016	Masonic Cancer Center, University of Minnesota	Phase 1
Terminated	Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndr NCT01572636	Masonic Cancer Center, University of Minnesota	—
Completed	Neurobehavioral Phenotypes in MPS III NCT01873911	University of Minnesota	—
Completed	Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders NCT01043640	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	Intrathecal Enzyme Replacement for Hurler Syndrome NCT00638547	Masonic Cancer Center, University of Minnesota	Phase 1
Withdrawn	Effects of Growth Hormone in Chronically Ill Children NCT00286689	University of Texas Southwestern Medical Center	N/A
Completed	Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease NCT00258011	Genzyme, a Sanofi Company	Phase 3
Completed	Stem Cell Transplant w/Laronidase for Hurler NCT00176891	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Y NCT00146757	Genzyme, a Sanofi Company	Phase 2
No Longer Available	BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BP NCT03639844	Bellicum Pharmaceuticals	—